You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR AVSOLA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for AVSOLA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04305145 ↗ Infliximab for Treatment of Ipilimumab Colitis Recruiting Massachusetts General Hospital Phase 2 2020-08-31 This research study is evaluating the effectiveness and safety of infliximab therapy compared with steroids in the treatment of ipilimumab-induced colitis in patients with III/IV melanoma.
NCT05034536 ↗ Pembrolizumab + Infliximab for Metastatic Melanoma Not yet recruiting Massachusetts Institute of Technology Phase 2 2022-01-01 The purpose of this research is to test the safety and effectiveness of the investigational combination of pembrolizumab and infliximab in treating metastatic melanoma.
NCT05034536 ↗ Pembrolizumab + Infliximab for Metastatic Melanoma Not yet recruiting Massachusetts General Hospital Phase 2 2022-01-01 The purpose of this research is to test the safety and effectiveness of the investigational combination of pembrolizumab and infliximab in treating metastatic melanoma.
NCT05660746 ↗ Precise Infliximab Exposure and Pharmacodynamic Control Not yet recruiting National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 2/Phase 3 2023-02-01 Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease (CD). There are limited treatment options approved for use in children and adults with Crohn's disease. Physicians need better ways to inform decisions on treatment. The main reason for this research study is to determine if a computer program that calculates an individualized dose based on a patient's blood testing results (precision dosing) can better achieve the best possible response to infliximab compared to standard dosing (conventional dosing).
NCT05660746 ↗ Precise Infliximab Exposure and Pharmacodynamic Control Not yet recruiting Children's Hospital Medical Center, Cincinnati Phase 2/Phase 3 2023-02-01 Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease (CD). There are limited treatment options approved for use in children and adults with Crohn's disease. Physicians need better ways to inform decisions on treatment. The main reason for this research study is to determine if a computer program that calculates an individualized dose based on a patient's blood testing results (precision dosing) can better achieve the best possible response to infliximab compared to standard dosing (conventional dosing).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for AVSOLA

Condition Name

Condition Name for AVSOLA
Intervention Trials
Crohn Disease 1
Melanoma Stage III 1
Melanoma Stage IV 1
Metastatic Melanoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for AVSOLA
Intervention Trials
Melanoma 2
Drug-Related Side Effects and Adverse Reactions 1
Colitis 1
Crohn Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for AVSOLA

Trials by Country

Trials by Country for AVSOLA
Location Trials
United States 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for AVSOLA
Location Trials
Massachusetts 2
Wisconsin 1
Ohio 1
Indiana 1
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for AVSOLA

Clinical Trial Phase

Clinical Trial Phase for AVSOLA
Clinical Trial Phase Trials
Phase 2/Phase 3 1
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for AVSOLA
Clinical Trial Phase Trials
Not yet recruiting 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for AVSOLA

Sponsor Name

Sponsor Name for AVSOLA
Sponsor Trials
Massachusetts General Hospital 2
Massachusetts Institute of Technology 1
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for AVSOLA
Sponsor Trials
Other 4
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.